(All figures are presented in U.S. Dollars) Successfully closed the acquisition of the U.S. based Natroba™ business on July 26, 2024 Epuris sales volumes grew 29% compared to Q3 2023, continuing...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2024 after the market close on...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO"). Craig Mull, Interim Chief...

MISSISSAUGA, ON / ACCESSWIRE / September 24, 2024 / Cipher Pharmaceuticals Inc (TSX:CPH)(OTCQX:CPHRF) ("Cipher") today announced that it will be presenting and participating in 1x1 meetings at the...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it...

(All figures are presented in U.S. Dollars) Adjusted EBITDA was $3.1 million in Q2 2024, consistent with Q2 2023 Epuris sales volumes grew 13% compared to Q2 2023, continuing its growth trajectory...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2024 after the market close...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announces the signing of a definitive asset purchase agreement with ParaPRO LLC ("ParaPRO") and the closing of the...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put...

(All figures are presented in U.S. Dollars) Adjusted EBITDA in Q1 2024 was $3.6 million, an increase of 12.5% over Q1 2023 Epuris sales volumes grew 7.2% in the quarter over Q1 2023, continuing...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2024 after the market close on...

(All figures are presented in U.S. Dollars) Cash at December 31, 2023 was $39.8 million (CDN$52.7 million) or $1.66 per outstanding common share (CDN$2.20) Full year adjusted EBITDA of $12.7...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and full year of 2023 after the...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or "the Company") is proud to announce that its common shares are now trading on the OTCQX® Best Market ("OTCQX") under the symbol...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it has changed its auditors from Ernst & Young LLP ("Former Auditor") to RSM Canada LLP ("Successor...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to...

(All figures are presented in U.S. dollars) Revenue increased 27% quarter-over-quarter to $6.1 million EPS grew 155% to $0.28 per share in the quarter Cash on hand of US$42.1 million, generated...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the third quarter of 2023 on Thursday, November 9, 2023. The...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company"), today announced the final results of its substantial issuer bid (the "Offer"), which expired at 5:00 p.m. (Eastern Time) on...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company"), today provided a reminder of its previously announced substantial issuer bid (the "Offer" or "SIB") under which the Company has...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company"), is announcing its intention to commence a substantial issuer bid (the "Offer" or "SIB") pursuant to which the Company will offer...

(All figures are presented in U.S. dollars) Strong growth capital available with $36.3 million in cash and cash equivalents Net income increased by 32% year-over-year to $5.7 million EPS increased...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the second quarter of 2023 on Thursday, August 10, 2023. The...

Significant regulatory milestone reached by Moberg, paving the way for their commercial launch across 13 countries in Europe Cipher holds exclusive Canadian rights to MOB-015 and sees the approval...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before...

(All figures are presented in U.S. dollars) Cash on hand grew by $4.6 million to $33.4 million EPS increased 25% year-over-year to $0.10 Adjusted EBITDA1 of $3.2 million was higher than Q1 2022...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the first quarter of 2023 on Thursday, May 11, 2023. The Company...

Mississauga, Ontario--(Newsfile Corp. - April 18, 2023) - Cipher Pharmaceuticals (TSX: CPH), a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage...

(All figures are in U.S. dollars) Product revenue increased 9% to $12.5 million in 2022 EBITDA of $12.0 million, relatively flat YoY Cash at December 31, 2022 was $28.8 million (CDN$39 million) or...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the three and twelve months ended December 31, 2022 after market...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced completion and closing of a new credit facility (the "Credit Facility") with Royal Bank of Canada (RBC). The...

(All figures are presented in U.S. dollars) EPS increased YoY by $0.08 to $0.11 in the third quarter; Strengthened balance sheet and demonstrated continued positive cash flow, ending Q3 with $27.5...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2022 financial results on Thursday, November 10, 2022 after market close. The company...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to...

Experienced finance executive Bryan Jacobs, CPA, CA to join the Company as CFO, effective August 15, 2022. OAKVILLE, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or...

(All figures are in U.S. dollars) Drove 7% increase in product revenue to $3.5 million Generated $3.6 million in Adjusted EBITDA Total operating expenses declined 5% to $2.2 million Strong balance...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q2 2022 financial results on Thursday, August 11, 2022 after market close. The Company...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before...

(All figures are in U.S. dollars) Drove 60% increase in EPS to $0.08 Demonstrated a focus on execution as EBITDA increased 38% to $3.1 million Total operating expenses declined 25% to $2.5 million...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q1 2022 financial results on Thursday, May 12, 2022 after market close. The Company will...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has submitted a regulatory filing for the next...

Demonstrated growth in FY 2021 as EBITDA increased 46% to $11.8 million Disciplined cost structure led to an 18% reduction in SG&A 81% increase in EPS to $0.29 in FY2021 Strengthened cash flow...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021...

Royalty agreement granting Sun Pharmaceutical Industries Inc. exclusive right to market, sell and distribute Absorica, Absorica AG and Absorica LD in the U.S. extended through December 31, 2026...

Revenue for nine months ended September 30, 2021increases 4.1% to $16.1 million Adjusted EBITDA1 for nine months ended September 30, 2021 increases to $9.8 million Basic EPS for the nine months ended

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2021 financial results on Thursday, November 11, 2021. The company will hold a...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to renew...

Revenue increases 30% to $6.1 million, Adjusted EBITDA2 increases 40% to $4.1 million EPS increases 450% to $0.11 (CDN$0.141) Epuris revenue grows 63%, Absorica revenue grows 25% All figures in...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2021 financial results on Thursday, August 12, 2021. The company will hold a conference...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...